ADAM8 as a drug target in pancreatic cancer

ADAM8 as a drug target in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) has a grim prognosis with <5% survivors after 5 years. High expression levels of ADAM8, a metalloprotease disintegrin, are correlated with poor clinical outcome. We show that ADAM8 expression is associated with increased migration and invasiveness of PDAC c...

Full description

Bibliographic Details
Main Authors: Schlomann, Uwe, Koller, Garrit, Conrad, Catharina, Ferdous, Taheera, Golfi, Panagiota, Garcia, Adolfo Molejon, Höfling, Sabrina, Parsons, Maddy, Costa, Patricia, Soper, Robin, Bossard, Maud, Hagemann, Thorsten, Roshani, Rozita, Sewald, Norbert, Ketchem, Randal R., Moss, Marcia L., Rasmussen, Fred H., Tuveson, David A., Nimsky, Christopher, Bartsch, Jörg W., Miller, Miles Aaron, Lauffenburger, Douglas A
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering
Format: Article
Language:en_US
Published: Nature Publishing Group 2017
Online Access:http://hdl.handle.net/1721.1/106940

Internet

http://hdl.handle.net/1721.1/106940

Similar Items